Cancer

Showing   of 92 results

UH Rainbow physician researcher co-authors study showing experimental drug eliminates 75 percent of aggressive pancreatic tumors

John J. Letterio, MD, PhD, is Director, Angie Fowler Adolescent & Young Adult Cancer Institute at UH Rainbow, and Director of Developmental Therapeutics at Case Comprehensive Cancer Center.

Thumbnail image of Dr. Angela Jia's official headshot.

University Hospitals Seidman Cancer Center researchers Demonstrate Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Lead author, Dr. Angela Jia, MD, PhD, presented randomized Phase III results at ASTRO 2026.

Thumbnail image of the new Accela machine at Seidman Cancer Center.

University Hospitals Seidman Cancer Center hosts first international pre-launch event for Siemens Healthineers new Accela

University Hospitals Seidman Cancer Center hosted a contingent of international journalists, along with Siemens Healthineers, for the first pre-launch event for the highly anticipated Accela.

University Hospitals researchers find major increase in the use of MRI before prostate biopsy

Results published in JAMA Oncology.

Thumbnail image of COVID Protexi graphic

Scientists Turn COVID-19 Immune Memory into a Powerful New Ally Against Cancer

Celloram, Inc., University Hospitals and Case Western Reserve University unveil PROTEXI, a novel cancer vaccine platform advancing toward first-in-human clinical trials in sarcoma patients.

Thumbnail image of UH Connor Whole Health building in Beachwood, Ohio.

Insurance-Supported Integrative Oncology Program Improves Patients’ Symptoms

New Study Published in JCO Oncology Practice.

Thumbnail image of scientist Seth Field.

Harrington Discovery Institute Researchers Identify New Drug Targets for Hard-to-Treat Cancers

New study of human cancers published in Science Signaling.

Dee and Jimmy Haslam

Dee and Jimmy Haslam Make $12.5 Million Transformational Investment in Blood Cancer Research and Treatments at University Hospitals

Benefiting patients worldwide, funding accelerates chronic lymphocytic leukemia research and rare cancer drug development through the Oxford-Harrington Rare Disease Centre and UH Seidman Cancer Center.

Results are loading...